CORRESP

X4 PHARMACEUTICALS, INC.

61 North Beacon Street, 4th Floor

Boston, MA 02134

October 22, 2020

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attn:

Ada D. Sarmento

 

RE:

X4 Pharmaceuticals, Inc.

Registration Statement on Form S-3

File No. 333-249544

Acceleration Request

Requested Date: October 26, 2020

Requested Time: 4:00 p.m. Eastern Time

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Exchange Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-249544) (the “Registration Statement”) to become effective at 4:00 p.m. Eastern Time on Monday, October 26, 2020, or as soon thereafter as is practicable.

Once the Registration Statement has been declared effective, please orally confirm that event with Daniel I. Goldberg of Cooley LLP, counsel to the registrant, at (212) 479-6722 or with Courtney T. Thorne of Cooley LLP at (617) 937-2318.

[Signature page follows]


Sincerely,

 

X4 PHARMACEUTICALS, INC.

By:   /s/ Adam S. Mostafa
 

Adam S. Mostafa

Chief Financial Officer

 

cc:

Paula Ragan, Ph.D., Chief Executive Officer, X4 Pharmaceuticals, Inc.

Daniel I. Goldberg, Cooley LLP

Courtney T. Thorne, Cooley LLP